



저작자표시-비영리-변경금지 2.0 대한민국

이용자는 아래의 조건을 따르는 경우에 한하여 자유롭게

- 이 저작물을 복제, 배포, 전송, 전시, 공연 및 방송할 수 있습니다.

다음과 같은 조건을 따라야 합니다:



저작자표시. 귀하는 원저작자를 표시하여야 합니다.



비영리. 귀하는 이 저작물을 영리 목적으로 이용할 수 없습니다.



변경금지. 귀하는 이 저작물을 개작, 변형 또는 가공할 수 없습니다.

- 귀하는, 이 저작물의 재이용이나 배포의 경우, 이 저작물에 적용된 이용허락조건을 명확하게 나타내어야 합니다.
- 저작권자로부터 별도의 허가를 받으면 이러한 조건들은 적용되지 않습니다.

저작권법에 따른 이용자의 권리는 위의 내용에 의하여 영향을 받지 않습니다.

이것은 [이용허락규약\(Legal Code\)](#)을 이해하기 쉽게 요약한 것입니다.

[Disclaimer](#)

Risk Factors for Surgery in Patients with  
Intestinal Behçet's Disease During  
Anti-tumor Necrosis Factor-alpha  
Therapy

So Jung Han

Department of Medicine

The Graduate School, Yonsei University



Risk Factors for Surgery in Patients with  
Intestinal Behçet's Disease During  
Anti-tumor Necrosis Factor-alpha  
Therapy

So Jung Han

Department of Medicine

The Graduate School, Yonsei University

# Risk Factors for Surgery in Patients with Intestinal Behçet's Disease During Anti-tumor Necrosis Factor-alpha Therapy

Directed by Professor Jae Hee Cheon

The Master's Thesis  
submitted to the Department of Medicine,  
the Graduate School of Yonsei University  
in partial fulfillment of the requirements for the degree of  
Master of Medical Science

So Jung Han

December 2022

This certifies that the Master's Thesis  
of So Jung Han is approved.

[Signature]

---

Thesis Supervisor : Jae Hee Cheon

[Signature]

---

Thesis Committee Member#1 : Jihye Park

[Signature]

---

Thesis Committee Member#2 : Min Soo Cho

The Graduate School  
Yonsei University

December 2022

## <TABLE OF CONTENTS>

ABSTRACT.....	iv
I. INTRODUCTION.....	1
II. MATERIALS AND METHODS.....	2
1.Study population.....	2
2.Assessments.....	3
3.Statistical analysis.....	5
III. RESULTS.....	5
1.Comparisons of baseline clinical characteristics and endoscopic findings.....	5
2.Surgery after anti-TNF- $\alpha$ therapy.....	8
3.Identification of risk factors for surgery.....	8
IV. DISCUSSION.....	10
V. CONCLUSION.....	13
REFERENCES.....	14
ABSTRACT(IN KOREAN).....	18

## LIST OF FIGURES

Figure 1. Kaplan - Meier curves of cumulative surgery-free survival for univariate factors.....	9
--	---

## LIST OF TABLES

Table 1. Baseline Patient Characteristics.....	6
Table 2. Baseline Endoscopic Characteristics.....	7
Table 3. Five predictive factors for surgery in intestinal BD patients after anti-TNF- $\alpha$ treatment.....	10



<ABSTRACT>

**Risk Factors for Surgery in Patients with Intestinal Behçet's Disease During Anti-tumor Necrosis Factor-alpha Therapy**

So Jung Han

*Department of Medicine  
The Graduate School, Yonsei University*

(Directed by Professor Jae Hee Cheon)

**Background/Aims:** Behçet's disease(BD) is a chronic inflammatory immune-mediated disease involving multiorgan systems. Gastrointestinal manifestations of BD include abdominal pain, vomiting, gastrointestinal bleeding, fistula formation, obstruction, and perforation that might require surgery. Recently, anti-TNF- $\alpha$  therapy has been shown to have favorable outcomes in patients with intestinal BD who are refractory to conventional therapy. This study sought to figure out the risk factors for undergoing surgery during anti-TNF- $\alpha$  therapy in patients with intestinal BD.

**Methods:** In this retrospective analysis of intestinal BD patients who were treated with anti-TNF- $\alpha$ , we collected the baseline patient data including comorbidities, clinical, endoscopic, and radiologic characteristics, and the Disease Activity Index for Intestinal Behçet's Disease at the time of anti-TNF- $\alpha$  initiation. Each potential risk factor was compared. For multivariate analysis, Cox regression was used.

**Results:** A total of 62 patients were considered eligible for analysis, and 15 of them (24.1%) underwent surgery. In univariate analysis, the presence of extraintestinal manifestation, such as joint symptoms and ESR, were significantly associated with surgery during therapy. In multivariate analysis, drug response within 4 weeks (HR 64.59), skin and joint manifestation (HR 10.23 and HR

6.22), geographic ulcer (HR 743.97), and ESR > 42.5 mm/hr (HR 9.16) were found to be factors predictive of undergoing surgery during anti-TNF- $\alpha$  therapy.

**Conclusion:** We found five risk factors predictive of surgery in patients with intestinal BD receiving anti-TNF- $\alpha$  therapy, which can guide physicians in selecting appropriate patients between anti-TNF- $\alpha$  therapy and early surgery.

---

Key words :intestinal behçet's disease, risk factors, tumor necrosis factor-alpha, surgery

## **Risk Factors for Surgery in Patients with Intestinal Behçet's Disease During Anti-tumor Necrosis Factor-alpha Therapy**

So Jung Han

*Department of Medicine  
The Graduate School, Yonsei University*

(Directed by Professor Jae Hee Cheon)

### I. INTRODUCTION

Behçet's disease (BD) is a chronic relapsing multisystemic inflammatory disease characterized by repeated oral and genital ulcerations, ocular lesions, skin manifestations, arthritis, vasculitis, and gastrointestinal (GI) involvement. Its etiology remains unknown, but many consider it a systemic vasculitis. <sup>1</sup> Approximately 3 - 16% of patients with BD have GI tract involvement. <sup>2</sup> Intestinal lesions may precede the extraintestinal manifestations. <sup>3</sup> Although the clinical manifestations of intestinal BD vary from mild abdominal pain to perforation and excessive bleeding, GI involvement in BD often suggests a poor prognosis despite treatment. <sup>1,4</sup>

Intestinal BD shares treatment strategies with inflammatory bowel diseases, such as Crohn's disease. <sup>4</sup> Although conventional therapies, 5-aminosalicylic acids, corticosteroids, and immunomodulators are available, considerable number of patients eventually become unresponsive to these pharmaceutical treatments. Biologic agents, such as anti-tumor necrosis factor-alpha (TNF- $\alpha$ ) agents have been approved for the treatment of intestinal BD and used as standard therapy, and they appear to be promising for more severe and/or refractory intestinal BD cases. <sup>1,5-8</sup> Infliximab, a

chimeric monoclonal anti-TNF- $\alpha$  antibody, and adalimumab, a completely humanized Immunoglobulin G1 monoclonal anti-TNF- $\alpha$  antibody, are the two most studied biologic agents.<sup>1</sup>

Despite the evident benefits of medical therapy, patients with intestinal BD often require surgery and may experience complications, such as intestinal perforation, bleeding, and abscess. Perforation and massive gastrointestinal bleeding are absolute indications for surgery, while abdominal abscess, fistula, and stricture are possible indications. In addition, patients who are refractory to medical treatments, including corticosteroids and anti-TNF- $\alpha$  agents, require surgical intervention.<sup>9,10</sup> Factors that can predict which patients will show a poor response to anti-TNF- $\alpha$  therapy have not been well studied to date. These predictive factors could aid physicians in determining the appropriate therapeutic options. Surgery should be considered early for patients who are expected to have poor anti-TNF responsiveness.

Cumulative rates of surgical interventions for intestinal BD are reportedly 20% at 1 year, 27% - 33% at 5 years, and 31% - 46% at 10 years after diagnosis.<sup>11-13</sup> The surgery rate is expected to decrease after the initiation of anti-TNF- $\alpha$  therapy. However, it is not yet known which patients will require surgery despite the use of anti-TNF- $\alpha$ . Therefore, this study aimed to determine the risk factors for surgery in patients with intestinal BD receiving anti-TNF- $\alpha$  agents.

## II. MATERIALS AND METHODS

### 1. Study population

Hospitalized or ambulatory patients with intestinal BD who were 18–80 years of age were eligible for enrollment in this study. We reviewed the medical records of patients with intestinal BD who underwent anti-TNF- $\alpha$  treatment at Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea, between February 2014 and June 2020. (IRB number : 2022-1254-001, IRB

institution : Severance hospital) The diagnosis of intestinal BD was confirmed in all patients using the established Korean and Japanese criteria.<sup>14,15</sup> Patients with definite, probable, or suspected intestinal BD were included. The analysis included all patients whose records were available at the time of anti-TNF- $\alpha$  treatment initiation, even if the treatment was first started at another hospital.

In patients with uncontrolled moderate or severe symptoms despite conventional medical therapy, two anti-TNF- $\alpha$  agents were typically considered.<sup>8,11</sup> Infliximab 5 mg/kg was administered at 0, 2, and 6 weeks and every 8 weeks thereafter. Adalimumab 160 mg was administered at week 0, 80 mg at week 2, and 40 mg at week 4, followed by 40 mg for maintenance every other week.<sup>16</sup> Patients who were taking anti-TNF- $\alpha$  for causes other than intestinal BD (*e.g.*, rheumatic diseases, such as ankylosing spondylitis) were excluded from the analysis.

Surgery was defined as resection of the small bowel, colon, or rectum after the initiation of anti-TNF- $\alpha$  therapy. Surgery was considered for patients whose symptoms were intractable to medical therapy or for those with complications, such as perforation, abscess, fistula, stricture, or gastrointestinal bleeding.<sup>8,17,18</sup>

## 2. Assessments

The medical records included baseline demographics (sex, age, age at diagnosis, alcohol intake, smoking status, and hematologic comorbidities), clinical information at the start of anti-TNF- $\alpha$  therapy (fever, oral ulcers, genital ulcers, eye symptoms, skin symptoms, joint symptoms, vascular symptoms, and neurologic symptoms), and the Disease Activity Index for Intestinal Behçet's Disease (DAIBD) score. The DAIBD score includes general well-being for 1 week, extraintestinal manifestations, abdominal pain in 1 week, abdominal mass,

abdominal tenderness, intestinal complications, and the number of liquid stools in 1 week.<sup>1,19</sup> DAIBD was classified as moderate for a score of 40 or higher and severe for a score of 75 or higher; all patients in this study were classified into the moderate or severe group. All clinical manifestations (fever and extraintestinal symptoms) were reviewed at the time of anti-TNF- $\alpha$  administration. Blood tests included hemoglobin level (mg/dL), erythrocyte sedimentation rate (mm/h), C-reactive protein level (mg/L), and recent imaging or endoscopic studies.

Typical ulcers in intestinal BD are single or few, large, deep, discrete, and round or oval-shaped.<sup>20,21</sup> The most common intestinal BD invasion site is the ileocecal area<sup>4</sup>; therefore, a case involving only one bowel segment was considered localized distribution. The macroscopic findings of the ulcers were categorized into the volcano-like, geographic, and aphthous types,<sup>22</sup> and the depth of each was reviewed. These were collected using the most recent colonoscopy results from the first anti-TNF- $\alpha$  dose.

Remission rates 8 weeks after the initiation of medical treatment for intestinal BD are reportedly 38–67%.<sup>21,23</sup> Four weeks after the first anti-TNF- $\alpha$  administration, the drug response was evaluated by an expert in an outpatient or in-hospital setting and the DAIBD score determined. We defined anti-TNF response as global gastrointestinal symptom scores and endoscopic assessments. Complete remission, marked improvement, improvement, and no change were included regardless of confirmation of mucosal healing.<sup>24</sup> The causes of surgery (refractory abdominal pain, perforation, abscess, or obstruction) were evaluated on the basis of clinical symptoms and computed tomography findings.

Information on drugs (aminosalicylic acids, corticosteroids, azathioprine/6-mercaptopurine, methotrexate, colchicine, or cyclosporine A) concomitantly used with anti-TNF- $\alpha$  was collected. Corticosteroid use included both oral and intravenous routes. Regarding surgical history, only bowel resection

associated with intestinal BD was documented. Surgery only after the administration of the most recently administered anti-TNF- $\alpha$  was considered the main clinical outcome. This study complied with the Declaration of Helsinki and was approved by our institutional ethics committee (IRB number : 2022-1254-001).

### 3. Statistical analysis

Descriptive data are expressed as the mean  $\pm$  standard deviation when normally distributed, and as the median  $\pm$  interquartile range (25<sup>th</sup> to 75<sup>th</sup> percentiles) when non-normally distributed. The primary objective of the present study was to identify the risk factors for surgery in patients undergoing anti-TNF- $\alpha$  therapy. Continuous data were analyzed using the Student's t test (or Mann-Whitney test when data were not normally distributed), and categorical data were compared with Pearson's  $\chi^2$  test. Items with a p value  $<0.2$  and clinically significant endoscopic characteristics were included as variables in the multivariate analysis to correct for each effect. Not all of the patients with intestinal BD do reached endoscopic healing with medical treatment only. Since the event of surgery itself suggests that the severity has increased over time, we assumed that Cox regression would be more appropriate than logistic regression. A multivariate analysis using the Cox proportional hazards regression model including significant univariate factors (p  $<0.05$ ) determined the independent risk factors. Hazard ratio (HRs) and 95% confidence interval (CIs) for each risk factor were calculated. Statistical analyses were performed using SPSS version 26 (SPSS Inc., Chicago, IL, USA).

## III. RESULTS

### 1. Comparisons of baseline clinical characteristics and endoscopic findings

Overall, among the 753 patients with intestinal BD registered at our

clinic, 79 underwent anti-TNF- $\alpha$  therapy. After excluding those who underwent anti-TNF- $\alpha$  therapy for diseases other than intestinal BD and those whose records were not available at the time of the first anti-TNF- $\alpha$  dose, 62 patients were finally included. Among them, 56 (90.3%) were treated with adalimumab, and five (8.0%) were treated with infliximab. The patients' demographic and clinical characteristics are presented in Table 1.

Table 1 Baseline patient characteristics



	N=62	Surgery (n=15)	Non-surgery (n=47)	p-value
Age at diagnosis, years	40.37	39.93±12.2	40.51±14.6	0.891
Sex				0.977
Male	25	6 (40%)	19 (40.4%)	
Smoking history				0.237
Never smoker	52	11 (73.3%)	41 (87.2%)	
Alcohol drinking history				0.478
Never drinker	45	11 (73.3%)	34 (72.3%)	
Hematologic diseases	5	2 (13.3%)	3 (6.4%)	0.587
Anti-TNF- $\alpha$ * therapy				1.000
Adalimumab	56	14(93.3%)	42 (89.4%)	
Infliximab	5	1 (6.7%)	4 (8.5%)	
History of previous anti-TNF- $\alpha$	15	4 (26.7%)	11 (23.4%)	1.000
DAIBD <sup>†</sup>		140.0±13.8	130.4±7.25	0.527
Moderate	3	0 (0%)	3 (6.4%)	
Severe	59	15 (100%)	44 (93.6%)	
Response within 4 weeks	55	11 (73.3%)	44 (93.6%)	0.052
Associated symptoms				
Fever	6	3 (20%)	3 (6.4%)	0.146
Oral ulcer	16	4 (26.7%)	12 (25.5%)	1.000
Genital ulcer	3	0 (0%)	3 (6.4%)	1.000
Eye symptom	3	1 (6.7%)	2 (4.3%)	1.000
Skin symptom	6	3 (20%)	3 (6.4%)	0.146
Joint symptom	6	5 (33.3%)	1 (2.1%)	0.002
Vascular symptom	1	0 (0%)	1 (2.1%)	1.000
Neurologic symptom	0	0 (0%)	0 (0%)	0.766
Hemoglobin (g/dL)		11.1±1.59	11.3±1.77	
Anemia		12 (80%)	32 (68.1%)	0.519
ESR <sup>§</sup> (mm/hr)		63.4±38.4	50.3±31.6	0.190
CRP <sup>¶</sup> (mg/L)		39.2(6.72-55.10)	27.12(3.20-38.3)	0.303
Medications				
Aminosalicylic acid	60	14 (93.3%)	46 (97.9%)	0.428
Corticosteroids	36	9 (8.7%)	27 (57.4%)	0.861
Azathioprine/6-mercaptopurine	30	7 (46.7%)	23 (48.9%)	0.878
Methotrexate	7	0 (0%)	7 (14.9%)	0.180
Colchicine	5	0 (0%)	5 (10.6%)	0.323
Cyclosporine A	1	1 (6.7%)	0 (0%)	0.242

\*Anti-tumor necrosis factor alpha; <sup>†</sup>Disease Activity Index for Intestinal Behçet's Disease; <sup>§</sup>erythrocyte sedimentation rate; <sup>¶</sup>C-reactive protein.

Twenty-five patients (40.3%) were male. There was no significant difference in the age at diagnosis between the surgery and non-surgery groups. The presence of hematologic comorbidities (*e.g.*, myelodysplastic syndrome) did not differ significantly between groups ( $p = 0.587$ ). The DAIBD score, which indicates intestinal BD severity, did not differ significantly between groups. The most common associated symptom was oral ulcer (25.85%). There were no significant differences in the associated extraintestinal manifestations between groups, except for a significant difference in the presence of joint symptoms (33.3% vs. 2.1%;  $p < 0.05$ ).

Sixty patients (96.7%) received aminosalicic acids, and 37 (59.6%) received immunomodulators (methotrexate or azathioprine/6-mercaptopurine). A total of 36 patients (58.0%) received corticosteroid therapy at varying doses. Twenty-four percent ( $n = 15$ ) had previously used other anti-TNF- $\alpha$  agents. There were no significant intergroup differences in medication use.

Table 2. Baseline endoscopic characteristics

	N=62	Surgery (n=15)	Non-surgery (n=47)	Log-rank test (p-value)
Ulcer shape				0.407
Geographic or volcano	2	1 (7.7%)	1 (2.3%)	
Oval, round, aphthous	55	12 (92.3%)	43 (97.7%)	
Number of ulcers				0.757
Multiple ( $\geq 2$ )	24	6 (40%)	18 (38.3%)	
Ulcer depth				0.370
Shallow	8			
Deep	48	10 (76.9%)	38 (88.4%)	
Ulcer type				0.580
Typical	51	13 (100%)	38 (88.4%)	
Ulcer distribution				0.711
Localized	44	11 (84.6%)	33 (76.7%)	

Next, we compared the most recent endoscopy results performed before the start of the anti-TNF- $\alpha$  agent (Table 2). Since a radiologic imaging study (*e.g.*, computed tomography) is preferred to endoscopy to determine the treatment plan in patients with the acute exacerbation of intestinal BD, the interval between endoscopic assessment and drug administration varied in our study (average 392 days, median 168.5, Q1 52.25 days- Q3 637 days). Forty-eight patients (77.4%) had deep ulcers; of them, 44 (70.9%) were localized in the short intestinal segment. Fifty-five patients (88.7%) had a typical intestinal BD ulcer shape on the most recent endoscopy. There were no significant intergroup differences in ulcer number, depth, type, or distribution.

Four weeks after the start of anti-TNF- $\alpha$  treatment, the response, including the DAIBD, was checked at the outpatient or in-hospital level. Of the 55 patients who showed a favorable response at 4 weeks, 11 underwent surgery after treatment. Patients who experienced a 4-week improvement were not significantly different between the surgery group and non-surgery group. (73.3% vs. 93.6%,  $p = 0.052$ ).

## 2. Surgery after anti-TNF- $\alpha$ therapy

Fifteen (24%) patients underwent bowel resection during the follow-up period. The mean patient age at the time of surgery was 47.1 years. The shortest mean time from the first drug administration to surgery was 602 days (range, 51 - 1,627 days). The reasons for surgery were refractory abdominal pain (7 patients [46.6%]), intractability with medical treatment (5 patients [33.3%]), abscess (with or without perforation) (1 patient [6.6%]), bowel perforation (2 patients [13.3%]), and bleeding (3 patients [20%]), considering multiple choices. In cases of surgery due to medical intractability, intestinal perforation was confirmed postoperatively.

### 3. Identification of risk factors for surgery

Multivariate analysis using Cox regression was performed for the most significant ( $p < 0.2$ ) factors and clinically significant endoscopic factors (ulcer shape, ulcer depth) to determine which were independent. The multivariate analysis identified five independent risk factors associated with surgical intervention: skin symptoms (hazard ratio [HR], 10.23; 95% confidence interval [CI], 1.66-62.99), joint symptoms (hazard ratio [HR], 6.22; 95% confidence interval [CI], 1.49-26.01), volcano type or geographic ulcer (HR, 743.97; 95% CI, 20.09-27550.25), erythrocyte sedimentation rate (ESR)  $>42.5$  mm/h (HR, 9.16; 95% CI, 1.33-62.78), and poor response in 4 weeks (HR, 64.59; 95% CI, 6.02-693.31) (Table 3).

Table 3. Five predictive factors for surgery in intestinal BD patients after anti-TNF- $\alpha$  treatment

	HR*	95% CI <sup>†</sup>	p-value
Skin symptoms (with vs. without)	10.23	1.66-62.99	<0.05
Joint symptoms (with vs. without)	6.22	1.49-26.01	<0.05
Ulcer shape (geographic or volcano type ulcer vs. oral, round, and so on)	743.97	20.09-27550.25	<0.05
Erythrocyte sedimentation rate ( $\geq 42.5$ vs. $<42.5$ )	9.16	1.33-62.78	<0.05
Response within 4 weeks (no vs. yes)	64.59	6.02-693.31	<0.05

\*Hazard ratio; <sup>†</sup>confidence interval

## IV. DISCUSSION

Intestinal BD often presents with concurrent symptoms of recurrent oral and genital aphthous ulcerations, arthritis, and skin manifestations with ocular, vascular, and neurological involvement. It shows a fluctuating clinical course with repeated episodes of relapse and remission. The symptoms can range from mild

abdominal discomfort to massive bleeding, fistula, or bowel perforation. Since patients with intestinal BD require lifelong treatment, clinicians should be aware of predictive factors for drug response. In particular, identifying the risk factors for surgery after or during treatment with anti-TNF agents are of clinical importance, since it remains unclear whether anti-TNF agents or surgery is more appropriate for patients for whom conventional therapy fails.

In this study, 15 of 62 patients were treated surgically for intestinal BD during the follow-up period. Surgery was mainly performed in response to medical therapy intractability. Patients who did not show a favorable response in a month, who had skin or joint symptoms at the initiation of anti-TNF- $\alpha$  therapy, who had volcano-like or geographic ulcers, or whose ESR was higher than 42.5 were at a higher risk of surgery.<sup>11,12,17,24</sup> In a retrospective review, younger age ( $\leq 25$  years) at diagnosis, a history of prior laparotomy, and volcano-shaped intestinal ulcers were identified as independent risk factors for free bowel perforation.<sup>25</sup> Patients with volcano-type ulcers reportedly show a significantly lower complete remission rate in response to initial medical therapy compared to those with non-volcano-type ulcers.<sup>22</sup> Therefore, the risk of surgery could be higher in patients with geographic or volcano-type ulcers, as shown in this study. In medically treated intestinal BD patients, a volcano-shaped ulcer was predictive of the likelihood of surgery.<sup>22,23</sup> The difference between our results and those of previous studies was that ulcer depth was not significantly associated with surgery. The reason is assumed to be that most of patients' ulcerations were deep.

Another study showed that patients who achieved complete remission of their intestinal lesions after 8 weeks of medical treatment had a lower probability of requiring surgery compared to those who did not.<sup>21</sup> In a multicenter retrospective study, which investigated the effectiveness of infliximab, the achievement of remission at week 4 were found to be one of the predictive

factors of sustained response in intestinal BD.<sup>27</sup> In this paper, response evaluations of 0, 2, 4, 30, and 54 weeks were included. This is most likely due to the finding that anti-TNF- $\alpha$  is a rapidly acting drug and a patient who fails to respond early has a low possibility of developing a good response later in the treatment process. This finding was consistent with our analysis showing a favorable response at 4 weeks as an independent risk factor for subsequent surgery. This implies that the early assessment of treatment response after anti-TNF- $\alpha$  initiation is valuable for predicting future prognosis.

In a previous study, the younger group of patients diagnosed at 40 years of age or younger showed a higher cumulative probability of requiring surgery,<sup>12</sup> but we found no significant difference between surgery and age at diagnosis in this study. A Korean multicenter retrospective study of 28 patients who were treated with infliximab demonstrated that older age (>40 years), female sex, longer disease duration (>5 years), concomitant immunomodulator use, and achievement of remission within 4 weeks were predictive of a sustained response.<sup>26</sup> To date, consistent results are lacking on this issue; therefore, further studies are warranted.

In this study, a higher C-reactive protein (CRP) level did not significantly increase the risk of surgery at any cut-off value; but in the case of ESR, ESR >42.5 mm/h significantly increased the odds of surgery. According to previous studies, ESR and CRP were correlated with disease activity; therefore, it can be inferred that disease activity with a higher inflammatory burden at the time of administration also affects subsequent surgery.<sup>1</sup>

These results are consistent with those of previous studies, which showed that extraintestinal symptoms in intestinal BD predict a poor prognosis. Each extraintestinal symptom count has a score of 1 in the DAIBD, and initial higher disease activity is an independent predictor of surgery and a severe disease course in intestinal BD<sup>12,24</sup>. In addition, extraintestinal symptoms are often accompanied

by pain, which can lower the patient's quality of life. Previous reports demonstrated that patients with extraintestinal symptoms show a poor prognosis for inflammatory bowel disease.<sup>27,28</sup>

Our study had several limitations. First, it was a single-center retrospective study with a relatively small sample size. Since one study has reported the postoperative recurrence of intestinal ulcers in more than half of patients<sup>30</sup> and that volcano-shaped ulcers and higher CRP levels increase the risk of reoperation,<sup>10</sup> a prospective observation is needed to confirm the risk factors. Also, the number of patients who had surgery was not large enough to make statistically significant result in our univariate analysis. Second, the doses of anti-TNF- $\alpha$  and other drugs (*e.g.*, steroids) could not be analyzed or adjusted. Further multicenter, longitudinal, long-term follow-up studies should consider the drug dose.

## V. CONCLUSION

In conclusion, our study is the first to reveal the predictive factors for surgery in patients with intestinal BD using anti-TNF- $\alpha$ . Surgery should be considered in a timely manner when an intestinal BD patient is suspected of having severe complications or does not respond properly to medical treatment.<sup>6,19</sup> In conclusion, we identified five risk factors predictive of surgery in patients with intestinal BD receiving anti-TNF- $\alpha$  therapy, which can guide physicians in selecting appropriate patients for anti-TNF- $\alpha$  therapy versus early surgery.

## REFERENCES

1. Skef W, Hamilton MJ, Arayssi T. Gastrointestinal Behcet's disease: a review. *World J Gastroenterol* 2015;21:3801-12.
2. Sakane T, Takeno M, Suzuki N, Inaba G. Behcet's disease. *N Engl J Med* 1999;341:1284-91.
3. Jung HC, Rhee PL, Song IS, Choi KW, Kim CY. Temporal changes in the clinical type or diagnosis of Behcet's colitis in patients with aphthoid or punched-out colonic ulcerations. *J Korean Med Sci* 1991;6:313-8.
4. Cha HJ, Kim K, Kim M, Choi H, Kim YM, Suh JH. Concurrent Gastric Adenocarcinoma of Fundic Gland Type and Carcinoma with Lymphoid Stroma: A Rare Case Report. *Case Rep Gastroenterol* 2016;10:292-301.
5. Watanabe K, Tanida S, Inoue N, Kunisaki R, Kobayashi K, Nagahori M, et al. Evidence-based diagnosis and clinical practice guidelines for intestinal Behcet's disease 2020 edited by Intractable Diseases, the Health and Labour Sciences Research Grants. *J Gastroenterol* 2020;55:679-700.
6. Cheon JH. Advances in Management of Intestinal Behcet's Disease: A Perspective From Gastroenterologists. *Journal of Rheumatic Diseases* 2021;28:4-16.
7. Kobayashi K, Ueno F, Bito S, Iwao Y, Fukushima T, Hiwatashi N, et al. Development of consensus statements for the diagnosis and management of intestinal Behcet's disease using a modified Delphi approach. *Journal of Gastroenterology* 2007;42:737-45.
8. Hisamatsu T, Ueno F, Matsumoto T, Kobayashi K, Koganei K, Kunisaki R, et al. The 2nd edition of consensus statements for the diagnosis and management of intestinal Behcet's disease: indication of anti-TNFalpha monoclonal antibodies. *J Gastroenterol* 2014;49:156-62.
9. Vicente CS, Freitas AD. Surgical treatment of intestinal perforation in



- Behcet Syndrome: an unusual presentation. *Pan Afr Med J* 2018;30:230.
10. Jung YS, Yoon JY, Lee JH, Jeon SM, Hong SP, Kim TI, et al. Prognostic factors and long-term clinical outcomes for surgical patients with intestinal Behcet's disease. *Inflamm Bowel Dis* 2011;17:1594-602.
  11. Park JJ, Kim WH, Cheon JH. Outcome predictors for intestinal Behcet's disease. *Yonsei Med J* 2013;54:1084-90.
  12. Jung YS, Yoon JY, Hong SP, Kim TI, Kim WH, Cheon JH. Influence of age at diagnosis and sex on clinical course and long-term prognosis of intestinal Behcet's disease. *Inflammatory Bowel Diseases* 2012;18:1064-71.
  13. Kim D-K, Yang S-K, Byeon J-S, Myung S-J, Jo J-Y, Choi KD, et al. Clinical Manifestations and Course of Intestinal Behet's Disease: An Analysis in Relation to Disease Subtypes. *Intest Res* 2005;3:48-54.
  14. Mizushima Y. Recent research into Behcet's disease in Japan. *Int J Tissue React* 1988;10:59-65.
  15. Criteria for diagnosis of Behcet's disease. International Study Group for Behcet's Disease. *Lancet* 1990;335:1078-80.
  16. Suzuki Y, Hagiwara T, Kobayashi M, Morita K, Shimamoto T, Hibi T. Long-term safety and effectiveness of adalimumab in 462 patients with intestinal Behcet's disease: results from a large real-world observational study. *Intest Res* 2021;19:301-12.
  17. Hisamatsu T, Hayashida M. Treatment and outcomes: medical and surgical treatment for intestinal Behcet's disease. *Intest Res* 2017;15:318-27.
  18. Baek SJ, Kim CW, Cho MS, Jang HA, Baik SH, Hur H, et al. Surgical Treatment and Outcomes in Patients With Intestinal Behcet Disease: Long-term Experience of a Single Large-Volume Center. *Dis Colon Rectum* 2015;58:575-81.
  19. Cheon JH, Han DS, Park JY, Ye BD, Jung SA, Park YS, et al.

- Development, validation, and responsiveness of a novel disease activity index for intestinal Behcet's disease. *Inflamm Bowel Dis* 2011;17:605-13.
20. Bayraktar Y, Ozaslan E, Van Thiel DH. Gastrointestinal manifestations of Behcet's disease. *J Clin Gastroenterol* 2000;30:144-54.
  21. Choi IJ, Kim JS, Cha SD, Jung HC, Park JG, Song IS, et al. Long-term clinical course and prognostic factors in intestinal Behcet's disease. *Dis Colon Rectum* 2000;43:692-700.
  22. Kim JS, Lim SH, Choi IJ, Moon H, Jung HC, Song IS, et al. Prediction of the clinical course of Behcet's colitis according to macroscopic classification by colonoscopy. *Endoscopy* 2000;32:635-40.
  23. Chung MJ, Cheon JH, Kim SU, Park JJ, Kim TI, Kim NK, et al. Response rates to medical treatments and long-term clinical outcomes of nonsurgical patients with intestinal Behcet disease. *J Clin Gastroenterol* 2010;44:e116-22.
  24. Miyazaki H, Watanabe D, Okamoto N, Tokunaga E, Ku Y, Takenaka H, et al. Efficacy and predictor of anti-TNFalpha agents in patients with intestinal Behcet's disease. *BMC Gastroenterol* 2022;22:149.
  25. Jung YS, Cheon JH, Park SJ, Hong SP, Kim TI, Kim WH. Clinical course of intestinal Behcet's disease during the first five years. *Dig Dis Sci* 2013;58:496-503.
  26. Moon CM, Cheon JH, Shin JK, Jeon SM, Bok HJ, Lee JH, et al. Prediction of Free Bowel Perforation in Patients with Intestinal Behcet's Disease Using Clinical and Colonoscopic Findings. *Digestive Diseases and Sciences* 2010;55:2904-11.
  27. Lee JH, Cheon JH, Jeon SW, Ye BD, Yang SK, Kim YH, et al. Efficacy of infliximab in intestinal Behcet's disease: a Korean multicenter retrospective study. *Inflamm Bowel Dis* 2013;19:1833-8.

28. Zeitz J, Ak M, Muller-Mottet S, Scharl S, Biedermann L, Fournier N, et al. Pain in IBD Patients: Very Frequent and Frequently Insufficiently Taken into Account. *PLoS One* 2016;11:e0156666.
29. Kim JM, Cheon JH. Pathogenesis and clinical perspectives of extraintestinal manifestations in inflammatory bowel diseases. *Intest Res* 2020;18:249-64.
30. Iida M, Kobayashi H, Matsumoto T, Okada M, Fuchigami T, Yao T, et al. Postoperative recurrence in patients with intestinal Behcet's disease. *Dis Colon Rectum* 1994;37:16-21.

<ABSTRACT(IN KOREAN)>

## 항 TNF제제 치료를 받고 있는 베체트 장염 환자에서 장절제 수술을 받을 위험 요소 분석

<지도교수 천재희>

연세대학교 대학원 의학과

한 소 정

**연구배경** 베체트 장염은 다장기침범을 하는 만성 염증성 면역 매개 질환이다. 베체트병의 위장관계 증상으로는 복통, 구토, 위장관계출혈, 누공 및 천공을 포함하며, 때때로 수술을 요하기도 한다. 최근 항 TNF제제가 기존의 치료에 충분한 반응이 없었던 환자들에게서 좋은 효과를 보이고있다. 따라서, 본 논문에서는 베체트 장염 환자들 중 항 TNF제제를 투약받은 경우 수술의 위험인자에 대해 알아보하고자 한다.

**방법** 베체트 장염 환자 중 항 TNF제제를 투약받은 환자들을 후향적으로 분석하였다. 약제 투약 시작 시점에서의 혈액질환과 같은 동반 질환을 비롯하여, 임상적, 내시경적, 영상 특징 및 베체트 장염 질병 활성도를 분석하였다.

**결과** 총 62명의 환자 중 15(24.1%)는 수술을 시행 받았다. 단변량 분석에서 피부 증상이나 관절 증상과 같은 장외증상을 가진 경우, 투약 당시 ESR이 42.5 mm/hr 이상인 경우와 4주 이내에 약제에 대한 반응 여부가 각각 수술 여부와 관련이 있는 것으로 나타났다. 또한, 임상적으로 중요한 내시경적 궤양의 모양과 깊이를 포함하여 다변량 분석을 시행하였다. 4주 이내에 약제에 반응이 없는 경우, 피부 또는 관절 증상을 동반한 경우, 내시경적으로 지도학적 모양을 나타내는 궤양이 확인된 경우, 그리고 투약 시 ESR이 42.5 mm/hr 이상인 경우가 항 TNF제제 사용 시 수술을 예측할 수 있는 인자로 나타났다.

**결론** 항 TNF제제 치료를 받는 베체트 장염 환자들에게서 수술을 받게 될 5가지의 위험요소들을 확인할 수 있었다. 이는 내과 의사들이 항 TNF제제 치료 또는 조기 수술을 결정해야 할 때 도움을 줄 수 있을 것으로 생각된다.

---

핵심되는 말 : 베체트 장염, 위험인자, 항 TNF제제, 수술